SCHEMBL1998427

SCHEMBL1998427

COC(=O)c1c(F)cc(F)c(F)c1F

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.47
TSHR P16473 1/20 0.46
MAPK1 P28482 1/20 0.46
CA1 P00915 4/20 0.45
CA2 P00918 4/20 0.45
CA4 P22748 2/20 0.45
CA12 O43570 2/20 0.43
CA7 P43166 2/20 0.43
CA9 Q16790 2/20 0.43
CA14 Q9ULX7 2/20 0.43
LMNA P02545 2/20 0.42
POLB P06746 2/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
KDM4E B2RXH2 1/20 0.42
GAA P10253 1/20 0.42
NFKB1 P19838 1/20 0.42
XDH P47989 1/20 0.42
GFER P55789 1/20 0.42
NFKB2 Q00653 1/20 0.42
RELA Q04206 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL522223 0.89 CA1 (0.52) MAPTTSHRMAPK1CA1CA2
SCHEMBL31386749 0.86 MAPT (0.40) MAPTTSHRMAPK1CA1CA2
SCHEMBL31386837 0.86 MAPT (0.40) MAPTTSHRMAPK1CA1CA2
SCHEMBL24445910 0.86 XDH (0.47) MAPTTSHRMAPK1CA1CA2
SCHEMBL24436891 0.86 CA12 (0.48) MAPTTSHRMAPK1CA1CA2
SCHEMBL24436894 0.86 XDH (0.47) MAPTTSHRMAPK1CA1CA2
SCHEMBL522850 0.86 MAPT (0.44) MAPTTSHRMAPK1CA1CA2
SCHEMBL28642417 0.84 MAPT (0.42) MAPTTSHRMAPK1CA1CA2
SCHEMBL24436890 0.83 CYP3A4 (0.52) MAPTTSHRMAPK1CA1CA2
SCHEMBL23169005 0.83 TSHR (0.44) MAPTTSHRMAPK1CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114478520-B Bcl-2 protein apoptosis inducer and application thereof 杭州和正医药有限公司 2025-01-10 CN disclosed
US-20230242705-A1 ESTER COMPOUND AND RESIN COMPOSITION AJINOMOTO CO., INC. (JP) 2023-08-03 US disclosed
CN-114478520-A Bcl-2 protein apoptosis inducer and application thereof 杭州和正医药有限公司 2022-05-13 CN disclosed
WO-2022089463-A1 BCL-2 PROTEIN APOPTOSIS-INDUCING AGENT AND APPLICATION THEREOF 杭州和正医药有限公司 2022-05-05 WO disclosed
US-8952083-B2 Fluorocopolymer composition and its production process ASAHI GLASS COMPANY, LIMITED (JP) 2015-02-10 US disclosed
EP-2338935-B1 FLUORINE-CONTAINING COPOLYMER COMPOSITION AND PROCESS FOR PRODUCTION THEREOF ASAHI GLASS CO LTD (JP) 2012-12-12 EP disclosed
US-20110172336-A1 FLUOROCOPOLYMER COMPOSITION AND ITS PRODUCTION PROCESS ASAHI GLASS COMPANY, LIMITED (JP) 2011-07-14 US disclosed
EP-2338935-A1 FLUORINE-CONTAINING COPOLYMER COMPOSITION AND PROCESS FOR PRODUCTION THEREOF ASAHI GLASS COMPANY, LIMITED (JP) 2011-06-29 EP disclosed
US-5407932-A Bactericides WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) 1995-04-18 US disclosed
EP-0393400-B1 Novel quinolone derivatives, preparation processes thereof, and antibacterial agents containing the same WAKUNAGA SEIYAKU KK (JP) 1994-12-21 EP disclosed
US-5245037-A Synthetic bactericides WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) 1993-09-14 US disclosed
EP-0393400-A1 Novel quinolone derivatives, preparation processes thereof, and antibacterial agents containing the same WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) 1990-10-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230242705-A1 ESTER COMPOUND AND RESIN COMPOSITION AFF4, AFF1, AFF2 MAPT 2274/4885TSHR 4043/4885MAPK1 4361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.